NCT04921670View on ClinicalTrials.gov

Infliximab Proactive Drug Monitoring in the Pediatric IBD Population

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

March 30, 2025

Study Completion Date

August 30, 2025

Conditions
Inflammatory Bone Disease
Interventions
DIAGNOSTIC_TEST

Infliximab Assay

Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion

Trial Locations (1)

48201

Children's Hospital of Michigan, Detroit

All Listed Sponsors
lead

Cares, Kristen, M.D.

OTHER